Trials / Withdrawn
WithdrawnNCT02096939
Microvascular Function in Primary Aldosteronism
Microvascular Function in Patients With Primary Aldosteronism and Essential Hypertension
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Patients with primary aldosteronism, which is the most prevalent form of secondary hypertension, have an increased rate of cardiovascular events, compared to patients with essential hypertension, even with equal severity of hypertension. This might be partially attributed to the association of increased aldosterone levels with insulin resistance. How this relation can be explained from a pathophysiological point of view, is insufficiently established. Recently, microvascular dysfunction has been proposed as a link between insulin resistance and hypertension. Loss of NO-mediated vasodilation is an important feature of microvascular dysfunction; in addition, an impaired insulin-mediated microvascular NO production has been suggested to underlie the reduction in insulin-stimulated glucose disposal that is characteristic of insulin-resistant states. Increased aldosterone levels are not only associated with insulin resistance, but also with endothelial dysfunction. In addition, they interfere with the vascular effects of insulin. Therefore, the investigators hypothesize that in patients with primary aldosteronism, increased aldosterone levels induce microvascular dysfunction through reduction of NO-availability, which contributes to the development of insulin resistance, and of hypertension, in addition to the sodium-retaining effects of aldosterone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Adrenal extirpation | |
| DRUG | Antihypertensive medication |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-03-26
- Last updated
- 2015-08-25
Source: ClinicalTrials.gov record NCT02096939. Inclusion in this directory is not an endorsement.